The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).
 
Elizabeth Chien Hern Liow
Travel, Accommodations, Expenses - Pfizer
 
Dickon Hayne
Consulting or Advisory Role - AstraZeneca; Mundipharma
Travel, Accommodations, Expenses - AstraZeneca
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Shomik Sengupta
No Relationships to Disclose
 
Paul Anderson
Honoraria - AstraZeneca; Procept Biorobotics
Consulting or Advisory Role - AstraZeneca; Juno Therapeutics
Research Funding - Procept Biorobotics
 
Kate Ford
No Relationships to Disclose
 
Mark Frydenberg
No Relationships to Disclose
 
Margot Gorzeman
No Relationships to Disclose
 
Will Green
No Relationships to Disclose
 
Jeremy Grummet
No Relationships to Disclose
 
Cynthia Hawks
Honoraria - Mundipharma
Travel, Accommodations, Expenses - Mundipharma
 
Laurence Eliot Miles Krieger
Honoraria - Astellas Pharma; Ferring; Ipsen; Janssen-Cilag; Janssen-Cilag; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbvie; Janssen-Cilag; Merck Sharp & Dohme; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Roche (Inst)
Expert Testimony - Astellas Pharma; Ipsen; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
 
Joseph Ischia
Honoraria - Astellas Pharma; Ipsen; Janssen; Mundipharma
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen; Mundipharma
Speakers' Bureau - Astellas Pharma; Ipsen; Janssen; Mundipharma
 
Steve McCombie
Travel, Accommodations, Expenses - Astellas Pharma
 
Manish Patel
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.